Thymosin Beta-4 for Sale From $68.00 — 1 Vendors (Jul 2026)

by Dr. Usman | Mar 30, 2022 | Research Thymosin Beta-4 has been documented by researchers to potentially play a role in protecting, regenerating, and remodeling damaged tissue cells. After any tissue injury, it is believed that Thymosin Beta-4 may be released by damaged cells to protect them and reduce the inflammatory process. This peptide is believed to be present in every tissue except red cells. Studies suggest that the first gene coding to occur (the process by which DNA and RNA dictate how and which cells need to form) after cell damage is Thymosin Beta-4. The formation of new blood vessels is believed to be essential to promote tissue repair. Damaged cells are believed to require early nutrients and supportive chemicals to reverse the damage. Thymosin Beta-4 is believed to have an angiogenic quality speculated to stimulate the migration and proliferation of endothelial cells.

Post-MI cardiac fibrosis replaces necrotic myocardium with collagen-rich scar tissue, reducing contractility and compliance. Tβ4’s regulation of cardiac fibroblast-myofibroblast transition is mechanistically complex: (i) anti-fibrotic component — Tβ4-ILK-Akt phosphorylates Smad3 at the linker region (Ser-204/208), promoting proteasomal Smad3 degradation and attenuating TGF-β1-driven myofibroblast differentiation; (ii) pro-repair component — Tβ4 promotes cardiac fibroblast migration and proliferation (collagen deposition for scar stabilisation). This apparent duality is time-dependent: acute Tβ4 treatment (24-48h post-MI) promotes fibroblast migration for early scar formation, while chronic Tβ4 (7-28d) normalises the TIMP:MMP ratio for collagen remodelling. Primary cardiac fibroblast (CF) isolation: neonatal rat or adult mouse heart (Langendorff retrograde perfusion, collagenase B, pre-plating 1h to enrich fibroblasts from cardiomyocyte contamination, vimentin+/troponin-T- purity ≥95%). TGF-β1 10 ng/mL (24-48h) drives myofibroblast differentiation (α-SMA stress fibre formation, FITC-phalloidin confocal; COL1A1 qPCR and Sircol; CTGF/CCN2 ELISA). Tβ4 (100 ng/mL-1 μg/mL) pre-treatment effects on TGF-β1-induced myofibroblast conversion: α-SMA western, Smad2/3 pS465/467 western (activation) versus pSer-204 linker (Akt-driven inhibition), ILK co-immunoprecipitation with Tβ4 (anti-Tβ4 antibody, Immundiagnostik K 41070). CF proliferation: BrdU ELISA in PDGF-BB (10 ng/mL) ± Tβ4 stimulated conditions. CF migration: Boyden 8 μm PET inserts, 4% FBS chemotaxis ± Tβ4.